Acquisition Adds Marketed Products and Specialty Sales Force in Urology and Endocrinology, Novel Drug-Delivery Technology

Combined Pipeline to Include Nine FDA-Approved Therapeutics

Conference Call Scheduled for Today at 5:30 pm EST

CHADDS FORD, Pa. and LEXINGTON, Mass., Jan. 5 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals and Indevus Pharmaceuticals, Inc...

SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Alternext US: ANX) announced today that it has implemented a further reduction-in-force in an effort to extend its remaining cash and to prepare itself for a strategic transaction. This follows a reduction implemented in October 2008. In all, the Company's workforce has declined by approximately 55% since the beginning...

BALTIMORE, Jan. 6 /PRNewswire/ -- FASgen, Inc. is pleased to announce that it has entered into a research and license agreement with Centocor, Inc. This agreement will give Centocor, Inc. and its Ortho Biotech Oncology Research and Development division affiliates the opportunity to discover and develop novel small molecule inhibitors of the fatty acid biosynthesis pathway via selective inhibition of...

PALO ALTO, Calif., Jan. 6 /PRNewswire/ -- Anacor Pharmaceuticals today announced that it has raised $50 million through a preferred stock financing with participation from GlaxoSmithKline, Schering Corporation and existing investors including Rho Capital Partners, Venrock Associates, Care Capital and Aberdare Ventures. Proceeds from the financing will be used to further develop Anacor's product pipeline...

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO - News), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced receipt of $5.5 million from Baxter Healthcare Corporation representing the final prepaid product-based payment due...

MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc. today announced the appointment of Dominick C. Colangelo as Chief Executive Officer and a member of the companys board of directors. Mr. Colangelo joins Promedior after a nearly 15-year pharmaceutical industry career at Eli Lilly and Company and most recently as Executive Vice President, Corporate Development and Operations at Oscient Pharmaceuticals...

SAN FRANCISCO--(BUSINESS WIRE)--Gryphon Investors, a San Francisco-based private equity firm, announced today that Susan C. Thornton, Ph.D., has been named President and CEO of Synteract Corporation, the holding company that owns Synteract, Inc. and Vince & Associates Clinical Research (VNA). Synteract Corporation was formed in September, 2008 when Synteract, Inc. and VNA were simultaneously recapitalized...

Immunogen Inc., the Waltham-based biotechnology company, announced the departure of CEO Mitchell Sayare and the installment of Daniel Junius as the new CEO. Sayare will continue to serve as Chairman of the Board and as a director of the company.

LONDON, Jan 6 (Reuters) - Ark Therapeutics said on Tuesday that European officials have agreed to accept its brain cancer drug Cerepro for submission.

LONDON, Jan 6 (Reuters) - AstraZeneca hopes to sell a nasal spray flu vaccine that is already available in the United States in Europe as well.